Microalbuminuria in cerebrovascular disease: A modifiable risk factor?

International Journal of Stroke

Volumn 5, Issue 1, 2010, Pages 30-34

  Rocco, A ^a   Heerlein, K ^a   Diedler, J ^a   Sykora, M ^a   Barrows, R ^a   Hacke, W ^a   Steiner, T H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cerebrovascular diseases (CVD); Microalbuminuria (MA); Mortality; Prognosis; Risk factors; Stroke

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAMIPRIL; RENIN INHIBITOR; TELMISARTAN; VALSARTAN;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; MICROALBUMINURIA; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; RENAL PROTECTION; RETINOPATHY; REVIEW; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SEPSIS; URINALYSIS; VASCULAR ENDOTHELIUM;

ALBUMINURIA; CEREBROVASCULAR DISORDERS; DIABETES COMPLICATIONS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; NEUROPROTECTIVE AGENTS; PROGNOSIS; RESEARCH DESIGN; RISK FACTORS; SEPSIS;

EID: 73949151146     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2009.00398.x     Document Type: Review

References (43)

1. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol 2007, 6:182-7.
2. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW. American diabetes association: nephropathy in diabetes. Diabetes Care 2004, 27((Suppl. 1)):S79-83.
3. Kuo HK, Lin LY, Yu YH. Microalbuminuria is a negative correlate for cognitive function in older adults with peripheral arterial disease: results from the U.S. National Health and Nutrition Examination Survey 1999-2002. J Intern Med 2007, 262:562-70.
4. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989, 32:219-26.
5. Jensen JS, Borch-Johnsen K, Deckert T, Deckert M, Jensen G, Feldt-Rasmussen B. Reduced glomerular size- and charge-selectivity in clinically healthy individuals with microalbuminuria. Eur J Clin Invest 1995, 25:608-14.
6. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002, 51:1157-65.
7. Parving H-H, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006, 69:2057-63.
8. Atkins RC, Polkinghorne KR, Briganti EM, Shaw JE, Zimmet PZ, Chadban SJ. Prevalence of albuminuria in Australia: the AusDiab kidney study. Kidney Int 2004, (Suppl.)):S22-4. review
9. Purzycki Z, Wyrzykowski B, Gockowski K. The influence of exercise on albumin excretion rate in borderline hypertensives and in offspring of hypertensive parents. J Hum Hypertens 1997, 11:119-23.
10. Gould MM, Mohamed-Ali V, Goubet SA, Yudkin JS, Haines AP. Microalbuminuria: associations with height and sex in non-diabetic subjects. BMJ 1993, 306:240-2.
11. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997, 157:1413-8. review
12. Gerstein HC, Mann JF. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001, 286:421-6. HOPE Study Investigators.
13. Parving HH, Mogensen CE, Jensen HA, Evrin PE. Increased urinary albumin-excretion rate in benign essential hypertension. Lancet 1974, 1:1190-2.
14. Bigazzi R, Bianchi S, Campese VM, Baldari G. Prevalence of microalbuminuria in a large population of patients with mild to moderate essential hypertension. Nephron 1992, 61:94-7.
15. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996, 14:223-8.
16. Wachtell K, Ibsen H, Olsen MH. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003, 139:901-6.
17. Hillege HL, Janssen WM. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001, 249:519-26. Prevend Study Group.
18. Torun D, Sezer S, Arat Z, Pelit A, Yigit F, Ozdemir FN. The frequency of combined target organ damage and the beneficial effect of ambulatory blood pressure monitoring in never treated mild-to-moderate hypertensive patients. Int Heart J 2005, 46:1073-82.
19. Calviño J, Calvo C, Romero R, Gude F, Sánchez-Guisande D. Atherosclerosis profile and microalbuminuria in essential hypertension. Am J Kidney Dis 1999, 34:996-1001.
20. Verhave JC, Hillege HL. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 2005, 67:1967-73. PREVEND Study Group.
21. Gopal S, Carr B, Nelson P. Does microalbuminuria predict illness severity in critically ill patients on the intensive care unit? A systematic review. Crit Care Med 2006, 34:1805-10.
22. Rinaldi S, Adembri C, Grechi S, De Gaudio AR. Low-dose hydrocortisone during severe sepsis: effects on microalbuminuria. Crit Care Med 2006, 34:2334-9.
23. Liese AD, Hense HW, Döring A, Stieber J, Keil U. Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J Hum Hypertens 2001, 15:799-804.
24. Hallan H, Romundstad S, Kvenild K, Holmen J. Microalbuminuria in diabetic and hypertensive patients and the general population - consequences of various diagnostic criteria - the Nord-Trøndelag Health Study (HUNT). Scand J Urol Nephrol 2003, 37:151-8.
25. Yuyun MF, Khaw KT, Luben R. Microalbuminuria and stroke in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. J Intern Med 2004, 255:247-56.
26. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984, 310:356-60.
27. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997, 157:1413-8.
28. Al-Maskari F, El-Sadig M, Obineche E. Prevalence and determinants of microalbuminuria among diabetic patients in the United Arab Emirates. BMC Nephrol 2008, 9:1.
29. Bigazzi R, Bianchi S, Nenci R, Baldari D, Baldari G, Campese VM. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens 1995, 9:827-33.
30. Słowik A, Turaj W, Iskra T, Strojny J, Szczudlik A. Microalbuminuria in nondiabetic patients with acute ischemic stroke: prevalence, clinical correlates, and prognostic significance. Cerebrovasc Dis 2002, 14:15-21.
31. Guerrero-Romero F, Rodríguez-Morán M. Relationship of microalbuminuria with the diabetic foot ulcers in type II diabetes. J Diabetes Complications 1998, 12:193-6.
32. Beamer NB, Coull BM, Clark WM, Wynn M. Microalbuminuria in ischemic stroke. Arch Neurol 1999, 56:699-702.
33. Cao JJ, Biggs ML, Barzilay J. Cardiovascular and mortality risk prediction and stratification using urinary albumin excretion in older adults ages 68-102: the cardiovascular health study. Atherosclerosis 2008, 197:806-13.
34. Terao Y, Takada M, Tanabe T, Ando Y, Fukusaki M, Sumikawa K. Microalbuminuria is a prognostic predictor in aneurysmal subarachnoid hemorrhage. Intensive Care Med 2007, 33:1000-6.
35. Terao Y, Miura K, Ichinomiya T, Higashijima U, Fukusaki M, Sumikawa K. Admission microalbuminuria and neurologic outcomes in intensive care unit patients with spontaneous intracerebral hemorrhage. J Neurosurg Anesthesiol 2008, 20:163-8.
36. Nellemann B, Gormsen LC, Dollerup J. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care 2007, 30:3122-4.
37. Mogensen CE, Neldam S, Tikkanen I. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study. Br Med J 2000, 321:1440-4.
38. Diercks GF, Janssen WM, van Boven AJ. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol 2000, 86:635-8.
39. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002, 106:672-8. MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators.
40. Parving HH, Lehnert H. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-8. for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
41. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000, 355:253-9. Heart Outcomes Prevention Evaluation Study Investigators.
42. Telmisartan, Ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-59. The ONTARGET Investigators.
43. Anderson CS, Huang Y. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol 2008, 7:391-9. for the INTERACT Investigators.